Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Gene | ATM |
| Variant | R3008H |
| Impact List | missense |
| Protein Effect | loss of function - predicted |
| Gene Variant Descriptions | ATM R3008H does not lie within any known functional domains of the Atm protein (UniProt.org). R3008H demonstrates kinase activity in an in vitro assay and recruitment to DNA damage sites similar to wild-type Atm protein, but results in decreased Atm activation, altered irradiation-induced cell cycle checkpoint, partial loss of tumor suppressor function (PMID: 33239428), and failure to induce Tp53 target gene expression after DNA damage in patient-derived cells (PMID: 23585524), and therefore, is predicted to lead to a loss of Atm protein function. |
| Associated Drug Resistance | |
| Category Variants Paths |
ATM mutant ATM inact mut ATM R3008H ATM mutant ATM R3008X ATM R3008H |
| Transcript | NM_000051.4 |
| gDNA | chr11:g.108365360G>A |
| cDNA | c.9023G>A |
| Protein | p.R3008H |
| Source Database | RefSeq |
| Genome Build | GRCh38/hg38 |
| Transcript | gDNA | cDNA | Protein | Source Database | Genome Build |
|---|---|---|---|---|---|
| XM_006718843.5 | chr11:g.108365360G>A | c.9023G>A | p.R3008H | RefSeq | GRCh38/hg38 |
| NM_000051.4 | chr11:g.108365360G>A | c.9023G>A | p.R3008H | RefSeq | GRCh38/hg38 |
| XM_006718843 | chr11:g.108365360G>A | c.9023G>A | p.R3008H | RefSeq | GRCh38/hg38 |
| XM_017017790.2 | chr11:g.108365360G>A | c.9023G>A | p.R3008H | RefSeq | GRCh38/hg38 |
| XM_005271562.6 | chr11:g.108365360G>A | c.9023G>A | p.R3008H | RefSeq | GRCh38/hg38 |
| XM_011542840.4 | chr11:g.108365360G>A | c.9023G>A | p.R3008H | RefSeq | GRCh38/hg38 |
| NM_001351834.2 | chr11:g.108365360G>A | c.9023G>A | p.R3008H | RefSeq | GRCh38/hg38 |
| XM_011542840 | chr11:g.108365360G>A | c.9023G>A | p.R3008H | RefSeq | GRCh38/hg38 |
| NM_000051.3 | chr11:g.108365360G>A | c.9023G>A | p.R3008H | RefSeq | GRCh38/hg38 |
| XM_047426975.1 | chr11:g.108365360G>A | c.9023G>A | p.R3008H | RefSeq | GRCh38/hg38 |
| NM_000051 | chr11:g.108365360G>A | c.9023G>A | p.R3008H | RefSeq | GRCh38/hg38 |
| XM_047426976.1 | chr11:g.108365360G>A | c.9023G>A | p.R3008H | RefSeq | GRCh38/hg38 |
| XM_017017789.2 | chr11:g.108365360G>A | c.9023G>A | p.R3008H | RefSeq | GRCh38/hg38 |
| XM_005271562 | chr11:g.108365360G>A | c.9023G>A | p.R3008H | RefSeq | GRCh38/hg38 |
| XM_005271561 | chr11:g.108365360G>A | c.9023G>A | p.R3008H | RefSeq | GRCh38/hg38 |
| XM_017017789 | chr11:g.108365360G>A | c.9023G>A | p.R3008H | RefSeq | GRCh38/hg38 |
| NM_001351834.1 | chr11:g.108365360G>A | c.9023G>A | p.R3008H | RefSeq | GRCh38/hg38 |
| XM_005271562.5 | chr11:g.108365360G>A | c.9023G>A | p.R3008H | RefSeq | GRCh38/hg38 |
| XM_011542840.3 | chr11:g.108365360G>A | c.9023G>A | p.R3008H | RefSeq | GRCh38/hg38 |
| XM_017017790.3 | chr11:g.108365360G>A | c.9023G>A | p.R3008H | RefSeq | GRCh38/hg38 |
| XM_006718843.4 | chr11:g.108365360G>A | c.9023G>A | p.R3008H | RefSeq | GRCh38/hg38 |
| XM_017017790 | chr11:g.108365360G>A | c.9023G>A | p.R3008H | RefSeq | GRCh38/hg38 |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|
| ATM R3008H | esophagus small cell carcinoma | predicted - sensitive | Etoposide + Olaparib | Case Reports/Case Series | Actionable | In a clinical case study, the combination of Lynparza (olaparib) and Vepesid (etoposide) resulted in a partial response and 5.9 months of progression-free survival in a patient with small cell esophageal carcinoma harboring ATM R3008H (PMID: 35480123). | 35480123 |
| ATM R3008H | prostate cancer | predicted - sensitive | RP-3500 | Case Reports/Case Series | Actionable | In a Phase I/II trial (TRESR), RP-3500 treatment resulted in a 29% tumor reduction in a castration-resistant prostate cancer patient harboring ATM R3008H, who remained on treatment for more than 61 weeks (PMID: 37277454; NCT04497116). | 37277454 |
| ATM R3008H | prostate cancer | sensitive | Olaparib | FDA approved - On Companion Diagnostic | Actionable | In a Phase III trial (PROfound) that supported FDA approval, Lynparza (olaparib) improved progression-free survival (7.4 vs 3.6 mo, HR 0.34, p<0.001), objective response rate (33% vs 2%, OR 20.86, p<0.001), and median overall survival (18.5 vs 15.1 mo, HR 0.64, p=0.02) over control in metastatic prostate cancer patients harboring inactivating BRCA/ATM mutations as detected by approved assays, including ATM R3008H, HR was 1.04 in ATM-mutant group (PMID: 32343890; NCT02987543). | 32343890 detail... detail... |